Outcomes of Platinum-Sensitive Small-Cell Lung Cancer Patients Treated With Platinum/Etoposide Rechallenge: A Multi-Institutional Retrospective Analysis.
Authors
Genestreti, GTiseo, M
Kenmotsu, H
Kazushige, W
Di Battista, M
Cavallo, G
Carloni, F
Bongiovanni, A
Burgio, M
Casanova, C
Metro, G
Scarpi, E
Korkmaz, T
Selcuk, S
Kurup, Roopa
Califano, Raffaele
Affiliation
Department of Medical Oncology, AUSL Bologna, ItalyIssue Date
2015-04-24
Metadata
Show full item recordAbstract
Patients with small-cell lung cancer (SCLC) that progresses after first-line (FL) chemotherapy have a poor prognosis and second-line (SL) chemotherapy has limited efficacy. Patients whose disease relapses/progresses > 90 days after FL platinum-based treatment are considered platinum-sensitive and could be rechallenged with a similar regimen. We conducted a multicenter retrospective analysis to evaluate outcomes of SCLC patients rechallenged with platinum/etoposide.Citation
Outcomes of Platinum-Sensitive Small-Cell Lung Cancer Patients Treated With Platinum/Etoposide Rechallenge: A Multi-Institutional Retrospective Analysis. 2015: Clin Lung CancerJournal
Clinical Lung CancerDOI
10.1016/j.cllc.2015.04.006PubMed ID
25983005Type
ArticleLanguage
enISSN
1938-0690ae974a485f413a2113503eed53cd6c53
10.1016/j.cllc.2015.04.006
Scopus Count
Collections
Related articles
- Rechallenge treatment with a platinum-based regimen in patients with sensitive relapsed small-cell lung cancer.
- Authors: Naito Y, Yamada K, Imamura Y, Ishii H, Matsuo N, Tokito T, Kinoshita T, Azuma K, Hoshino T
- Issue date: 2018 Apr 2
- Outcomes of small-cell lung cancer patients treated with second-line chemotherapy: a multi-institutional retrospective analysis.
- Authors: Garassino MC, Torri V, Michetti G, Lo Dico M, La Verde N, Aglione S, Mancuso A, Gallerani E, Galetta D, Martelli O, Collovà E, Fatigoni S, Ghidini A, Saggia C, Bareggi C, Rossi A, Farina G, Thatcher N, Blackhall F, Lorigan P, Califano R
- Issue date: 2011 Jun
- Efficacy of rechallenge chemotherapy in patients with sensitive relapsed small cell lung cancer.
- Authors: Wakuda K, Kenmotsu H, Naito T, Akamatsu H, Ono A, Shukuya T, Nakamura Y, Tsuya A, Murakami H, Takahashi T, Endo M, Nakajima T, Yamamoto N
- Issue date: 2015 Feb
- Cisplatin, Etoposide, and Bevacizumab Regimen Followed by Oral Etoposide and Bevacizumab Maintenance Treatment in Patients With Extensive-Stage Small Cell Lung Cancer: A Single-Institution Experience.
- Authors: Petrioli R, Roviello G, Laera L, Luzzi L, Paladini P, Ghiribelli C, Voltolini L, Martellucci I, Bianco V, Francini E
- Issue date: 2015 Nov
- Dose Modification of Etoposide plus Platinum in Elderly Patients with Extensive-Disease Small-Cell Lung Cancer.
- Authors: Kim H, Choi E, Heo MH, Kim JY, Park KU
- Issue date: 2022